Gliclazide APi

Gliclazide APi

8000 INR/Kilograms

Product Details:

  • HS Code 29350090
  • Smell Other
  • Shelf Life 3 Years
  • Taste Other
  • Molecular Formula C15H21N3O3S
  • Molecular Weight 323.4 Kilograms (kg)
  • Storage Dry Place
  • Click to view more
X

Price And Quantity

  • 8000 INR/Kilograms
  • 100kg Kilograms

Product Specifications

  • 323.4 Kilograms (kg)
  • C15H21N3O3S
  • Antipyretic Analgesics and NSAIDs
  • Dry Place
  • Medicine Grade
  • Other
  • Gliclazide
  • Powder
  • 3 Years
  • 21187-98-4
  • 99
  • Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).
  • 29350090
  • Other

Trade Information

  • Cash Against Delivery (CAD), Cash Advance (CA), Cash in Advance (CID), Letter of Credit (L/C), Letter of Credit at Sight (Sight L/C)
  • 2 Week
  • Yes
  • Free samples are available
  • HDPE Drums
  • Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Product Description

Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group. On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life. Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating  cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic  cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%).
Enter Buying Requirement Details
Email Id
Mobile number

Other Products in 'APIs' category



We are exporting in the countries such as Afghanistan, Algeria, Argentina, Bolivia, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Indonesia, Iran, Jordan, Morocco, Panama, South Korea, Taiwan, Turkey, Uruguay, Vietnam and Yemen.
INDO PHARM All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.